On October 31, 2023 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 38th Annual Meeting in San Diego, CA, November 1-5, 2023 (Press release, Iovance Biotherapeutics, OCT 31, 2023, View Source [SID1234636531]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An abstract on the four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial reports the longest follow-up data on lifileucel treatment outcomes in the largest population of patients with anti–PD-1–refractory advanced melanoma treated with TIL therapy. As of the data cutoff date of June 16, 2023, median C-144-01 trial follow-up was 48.1 months in heavily pretreated patients with advanced melanoma. One-time lifileucel TIL therapy demonstrated durable efficacy with a four-year OS rate of 22.2%. The longest response was ongoing at 59.9 months. Treatment-emergent adverse events were consistent with known safety profiles of lymphodepletion and IL-2, and their incidence decreased over time. The four-year analysis further supports the use of lifileucel as a potential treatment option in these patients that is differentiated from other immunotherapies.

Iovance Posters at SITC (Free SITC Whitepaper) Annual Meeting

Long-term efficacy and safety of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study
Poster: Saturday, Nov. 4, 2023, 9:00 a.m.–8:30 p.m. PT
Tumor infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro
Poster: Friday, Nov. 3, 2023, 9:00 a.m.–7:00 p.m. PT
Trial-in-Progress: TILVANCE-301, a phase 3 study of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
Poster: Saturday, Nov. 4, 2023, 9:00 a.m.–8:30 p.m. PT